| Literature DB >> 28895854 |
Geoffrey L Rogers1, Paula M Cannon2.
Abstract
Advances in gene therapy technologies, particularly in gene editing, are suggesting new avenues for the treatment of human immunodeficiency virus and other infectious diseases. This article outlines recent developments in antiviral gene therapies, including those based on the disruption of entry receptors or that target viral genomes using targeted nucleases, such as the CRISPR/Cas9 system. In addition, new ways to express circulating antiviral factors, such as antibodies, and approaches to harness and engineer the immune system to provide an antiviral effect that is not naturally achieved are described.Entities:
Keywords: AAV; Cas9; Gene editing; Gene therapy; HIV; Targeted nuclease
Mesh:
Substances:
Year: 2017 PMID: 28895854 DOI: 10.1016/j.hoc.2017.06.008
Source DB: PubMed Journal: Hematol Oncol Clin North Am ISSN: 0889-8588 Impact factor: 3.722